Norethisterone acetate

Overview

Norethisterone acetate (NETA), also known as norethindrone acetate and sold under the brand name Primolut-Nor among others, is a progestin medication which is used in birth control pills, menopausal hormone therapy, and for the treatment of gynecological disorders. The medication is available in low-dose and high-dose formulations and is used alone or in combination with an estrogen. It is ingested orally.[1–6] WP

Side effects of NETA include menstrual irregularities, headaches, nausea, breast tenderness, mood changes, acne, increased hair growth, and others. NETA is a progestin, or a synthetic progestogen, and hence is an agonist of the progesterone receptor, the biological target of progestogens like progesterone. It has weak androgenic and estrogenic activity and no other important hormonal activity. The medication is a prodrug of norethisterone in the body.[1][5][7][8][9] WP

NETA was patented in 1957 and was introduced for medical use in 1964. It is sometimes referred to as a "first-generation" progestin. NETA is marketed widely throughout the world. It is available as a generic medication.[4][10–14] WP

Uses, dosage and effects

Medical uses

NETA is used as a hormonal contraceptive in combination with estrogen, in the treatment of gynecological disorders such as abnormal uterine bleeding, and as a component of menopausal hormone therapy for the treatment of menopausal symptoms.[4] WP

Available forms

NETA is available in the form of tablets for use by mouth both alone and in combination with estrogens including estradiol, estradiol valerate, and ethinylestradiol. Transdermal patches providing a combination of 50 μg/day estradiol and 0.14 or 0.25 mg/day NETA are available under the brand names CombiPatch and Estalis.[4][15] WP

NETA was previously available for use by intramuscular injection in the form of ampoules containing 20 mg NETA, 5 mg estradiol benzoate, 8 mg estradiol valerate, and 180 mg testosterone enanthate in oil solution under the brand name Ablacton to suppress lactation in postpartum women.[16–19] WP

Progestogenic effects

In terms of dosage equivalence, norethisterone and NETA are typically used at respective dosages of 0.35 mg/day and 0.6 mg/day as progestogen-only contraceptives, and at respective dosages of 0.5–1 mg/day and 1–1.5 mg/day in combination with ethinylestradiol in combined oral contraceptives. Conversely, the two drugs have been used at about the same dosages in menopausal hormone therapy for the treatment of menopausal symptoms. NETA is of about 12% higher molecular weight than norethisterone due to the presence of its C17β acetate ester. Micronization of NETA has been found to increase its potency by several-fold in animals and women. The endometrial transformation dosage of micronized NETA per cycle is 12 to 14 mg, whereas that for non-micronized NETA is 30 to 60 mg.[2][7][20–23] WP

Estrogenic effects

NETA metabolizes into ethinylestradiol at a rate of 0.20 to 0.33% across a dose range of 10 to 40 mg. Peak levels of ethinylestradiol with a 10, 20, or 40 mg dose of NETA were 58, 178, and 231 pg/mL, respectively. For comparison, a 30 to 40 μg dose of oral ethinylestradiol typically results in a peak ethinylestradiol level of 100 to 135 pg/mL. As such, in terms of ethinylestradiol exposure, 10 to 20 mg NETA may be equivalent to 20 to 30 μg ethinylestradiol and 40 mg NETA may be similar to 50 μg ethinylestradiol. In another study however, 5 mg NETA produced an equivalent of 28 μg ethinylestradiol (0.7% conversion rate) and 10 mg NETA produced an equivalent of 62 μg ethinylestradiol (1.0% conversion rate). Due to its estrogenic activity via ethinylestradiol, high doses of NETA have been proposed for add-back in the treatment of endometriosis without estrogen supplementation. Generation of ethinylestradiol with high doses of NETA may increase the risk of venous thromboembolism but may also decrease menstrual bleeding relative to progestogen exposure alone.[24–27] WP

Antigonadotropic effects

NETA has antigonadotropic effects via its progestogenic activity and can dose-dependently suppress gonadotropin and sex hormone levels in women and men. The ovulation-inhibiting dose of NETA is about 0.5 mg/day in women. In healthy young men, NETA alone at a dose of 5 to 10 mg/day orally for 2 weeks suppressed testosterone levels from ~527 ng/dL to ~231 ng/dL (–56%).[1][28][29][30] WP

Risks and side effects

Side effects

Side effects of NETA include menstrual irregularities, headaches, nausea, breast tenderness, mood changes, acne, increased hair growth, and others.[5] WP

Pharmacology

Pharmacodynamics

NETA is a prodrug of norethisterone in the body. Upon oral ingestion, it is rapidly converted into norethisterone by esterases during intestinal and first-pass hepatic metabolism. Hence, as a prodrug of norethisterone, NETA has essentially the same effects, acting as a potent progestogen with additional weak androgenic and estrogenic activity (the latter via its metabolite ethinylestradiol).[1][7][8][9] WP

Research

Research

NETA has been studied for use as a potential male hormonal contraceptive in combination with testosterone in men.[31] WP

History

History

Schering AG filed for a patent for NETA in June 1957, and the patent was issued in December 1960. The drug was first marketed, by Parke-Davis as Norlestrin in the United States, in March 1964. This was a combination formulation of 2.5 mg NETA and 50 μg ethinylestradiol and was indicated as an oral contraceptive. Other early brand names of NETA used in oral contraceptives included Minovlar and Anovlar.[10][11] WP

Legal status

Generic names

Norethisterone acetate is the INN (International Nonproprietary Name), BANM (British Approved Name), and JAN (Japanese Accepted Name) of NETA while norethindrone acetate is its USAN (United States Adopted Name) and USP (United States Pharmacopeia).[2][4] WP

Brand names

NETA is marketed under a variety of brand names throughout the world including Primolut-Nor (major), Aygestin (US (United States)), Gestakadin, Milligynon, Monogest, Norlutate (US (United States), CA (Canada)), Primolut N, SH-420 (UK (United Kingdom)), Sovel, and Styptin among others.[2][4] WP

United states

NETA is marketed in high-dose 5 mg oral tablets in the United States under the brand names Aygestin and Norlutate for the treatment of gynecological disorders. In addition, it is available under a large number of brand names at much lower dosages (0.1 to 1 mg) in combination with estrogens such as ethinylestradiol and estradiol as a combined oral contraceptive and for use in menopausal hormone therapy for the treatment of menopausal symptoms.[6][32] WP

Chemistry

Formula

C22H28O3 PC

CAS number

51-98-9 PC

Molar mass (g/mol)

340.5 PC

IUPAC name (computed by PubChem)

[(8R,9S,10R,13S,14S,17R)-17-ethynyl-13-methyl-3-oxo-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl] acetate PC

SMILES

CC(=O)O[C@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@H]34)C)C#C PC

InChIKey

IMONTRJLAWHYGT-ZCPXKWAGSA-N PC

PubChem CID

5832

Harm reduction information

No harm reduction data is on file for this compound yet. That means no dose, timing or combination data from PsychonautWiki or TripSit. Please don't guess a dose from similar compounds. If you have taken it and feel unwell, contact emergency services or a poison control center.

User reports

Pop culture

No references added yet.

Sources

1. Journal / agency Kuhl H. Pharmacology of estrogens and progestogens: influence of different routes of administration. Climacteric. August 2005. doi:10.1080/13697130500148875 · PMID 16112947
2. Other J. Elks. The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. 14 November 2014
3. Other Index Nominum 2000: International Drug Directory. 2000
4. Other Norethindrone Monograph for Professionals
5. Journal / agency AYGESTIN® (norethindrone acetate tablets, USP)
6. Journal / agency Drugs@FDA: FDA Approved Drug Products
7. Other IARC Working Group on the Evaluation of Carcinogenic Risks to Humans; World Health Organization; International Agency for Research on Cancer. Combined Estrogen-progestogen Contraceptives and Combined Estrogen-progestogen Menopausal Therapy. 2007
8. Other Thomas L. Lemke; David A. Williams. Foye's Principles of Medicinal Chemistry. 2008
9. Journal / agency Chwalisz K, Surrey E, Stanczyk FZ. The hormonal profile of norethindrone acetate: rationale for add-back therapy with gonadotropin-releasing hormone agonists in women with endometriosis. Reprod Sci. 2012. doi:10.1177/1933719112438061 · PMID 22457429
10. Other Lara Marks. Sexual Chemistry: A History of the Contraceptive Pill. 2010
11. Other Robert W. Blum. Adolescent Health Care: Clinical Issues. 22 October 2013
12. Other Robert Anthony Hatcher; Anita L. Nelson, M.D. Contraceptive Technology. 2007
13. Other Sulochana Gunasheela. Practical Management of Gynecological Problems. 14 March 2011
14. Other Generic Aygestin Availability
15. Other James M. Rippe. Lifestyle Medicine. 15 March 2013
16. Other A. Labhart. Clinical Endocrinology: Theory and Practice. 6 December 2012
17. Other F. G. Sulman. Hypothalamic Control of Lactation: Monographs on Endocrinology. 22 October 2013
18. Other Ufer, Joachim. Hormontherapie in der Frauenheilkunde: Grundlagen und Praxis. 1 January 1978
19. Other Drugs. 1975
20. Other J. Horsky; J. Presl. Ovarian Function and its Disorders: Diagnosis and Therapy. 6 December 2012
21. Other Janet Brotherton. Sex Hormone Pharmacology. 1976
22. Journal / agency Gibian H, Kopp R, Kramer M, Neumann F, Richter H. Effect of particle size on biological activity of norethisterone acetate. Acta Physiol Lat Am. 1968. PMID 5753386
23. Journal / agency He CH, Shi YE, Liao DL, Zhu YH, Xu JQ, Matlin SA, Vince PM, Fotherby K, Van Look PF. Comparative cross-over pharmacokinetic study on two types of postcoital contraceptive tablets containing levonorgestrel. Contraception. May 1990. doi:10.1016/0010-7824(90)90064-3 · PMID 2112080
24. Journal / agency Sitruk-Ware R, Nath A. Characteristics and metabolic effects of estrogen and progestins contained in oral contraceptive pills. Best Pract. Res. Clin. Endocrinol. Metab. February 2013. doi:10.1016/j.beem.2012.09.004 · PMID 23384742
25. Journal / agency Chu MC, Zhang X, Gentzschein E, Stanczyk FZ, Lobo RA. Formation of ethinyl estradiol in women during treatment with norethindrone acetate. J. Clin. Endocrinol. Metab. June 2007. doi:10.1210/jc.2007-0044 · PMID 17341557
26. Journal / agency Kuhnz W, Heuner A, Hümpel M, Seifert W, Michaelis K. In vivo conversion of norethisterone and norethisterone acetate to ethinyl etradiol in postmenopausal women. Contraception. 1997. doi:10.1016/s0010-7824(97)00174-1 · PMID 9494772
27. Journal / agency Vilk Ayalon N, Segev L, Samson AO, Yagel S, Cohen SM, Green T, Hochler H. Norethisterone Reduces Vaginal Bleeding Caused by Progesterone-Only Birth Control Pills. J Clin Med. June 2022. doi:10.3390/jcm11123389 · PMID 35743459 · PMC9224784
28. Journal / agency Endrikat J, Gerlinger C, Richard S, Rosenbaum P, Düsterberg B. Ovulation inhibition doses of progestins: a systematic review of the available literature and of marketed preparations worldwide. Contraception. December 2011. doi:10.1016/j.contraception.2011.04.009 · PMID 22078182
29. Journal / agency Zitzmann M, Rohayem J, Raidt J, Kliesch S, Kumar N, Sitruk-Ware R, Nieschlag E. Impact of various progestins with or without transdermal testosterone on gonadotropin levels for non-invasive hormonal male contraception: a randomized clinical trial. Andrology. May 2017. doi:10.1111/andr.12328 · PMID 28189123
30. Journal / agency Kamischke A, Diebäcker J, Nieschlag E. Potential of norethisterone enanthate for male contraception: pharmacokinetics and suppression of pituitary and gonadal function. Clin Endocrinol (Oxf). September 2000. doi:10.1046/j.1365-2265.2000.01097.x · PMID 10971453
31. Journal / agency Nieschlag E. Clinical trials in male hormonal contraception. Contraception. 2010. doi:10.1016/j.contraception.2010.03.020 · PMID 20933120
32. Journal / agency Drugs@FDA: FDA Approved Drug Products

Text and values on this page are quoted from Wikipedia (CC BY-SA 4.0), PubChem (public domain). Each value links to the exact revision it came from.